Glioblastoma is the most frequent primary malignant brain tumor in adults. Despite
treatments including surgery, radiotherapy and chemotherapy by oral Temozolomide (TMZ) …

A photopolymerizable hydrogel-based local drug delivery system was developed for the
postsurgical treatment of glioblastoma (GBM). We aimed for a local drug combination …

Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor. Despite
available therapeutic options, the prognosis for patients with GBM remains very poor. We …

Overall survival of patients with newly diagnosed glioblastoma (GBM) remains dismal at 16
months with state-of-the-art treatment that includes surgical resection, radiation, and …

Introduction We have completed in vivo safety and efficacy studies of the use of a novel drug
delivery system, a gel matrix-temozolomide formulation that is injected intracranially into the …

With its ability to cross the blood-brain barrier, temozolomide (TMZ) is the first-line treatment
option in glioblastoma multiforme therapy. This study aims to design TMZ-loaded PLGA …

Current treatment strategies for Glioblastoma (GBM)—including surgery, radiotherapy, and
chemotherapy with oral administration of temozolomide (TMZ)—still lead to poor survival …

Many approaches to local tumor treatment have been reported and their efficacy
demonstrated in patients with malignant glioma. We studied thermoreversible gelation …

Among central nervous system tumors, Glioblastoma (GBM) is the most common, aggressive
and neurological destructive primary brain tumor in adults. Standard care therapy for GBM …

In this study, a methacrylic gelatin/oxidized dextran/montmorillonite‑strontium/polypyrrole
(GOMP) hydrogel was prepared. The GOMP hydrogel had dual network structure which was …